Recent research has found that sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with a lower risk for sight-threatening retinopathy than other second-line glucose-lowering medications in patients with Type 2 diabetes.
The five year study – involving 3,544,383 people with newly diagnosed Type 2 diabetes – saw 159,965 of them treated with SGLT2 inhibitors, 304,383 with dipeptidyl peptidase-4 (DPP-4) inhibitors, 108,420 with pioglitazone, and 189,618 with sulfonylurea.
The research found that SGLT2 inhibitors reduced sight-threatening retinopathy risk by 43% vs DPP-4 inhibitors, by 38% vs sulfonylurea, and by 25% vs pioglitazone.
This study was led by Fu-Shun Yen, MD, a private practitioner from Taiwan, and was published on December 20, 2023, in JAMA Network Open.
To find out more, CLICK HERE
